Hutchmed
-
EMA accepts Hutchmed’s MAA for surufatinib to treat pancreatic and extra-pancreatic neuroendocrine tumors
191 0Hutchmed announced that the European Medicines Agency (EMA) has validated…
Read more
Hutchmed announced that the European Medicines Agency (EMA) has validated…
Read more